FDA has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent, to treat people with ...

People with relapsing-remitting and active secondary-progressive multiple sclerosis (MS), as well as those with clinically isolated syndrome (CIS, an initial neurological episode), have a new ...

Genentech, a member of the Roche Group, has won FDA approval for the first treatment indicated for both relapsing and primary progressive forms of multiple sclerosis (MS). Ocrevus™ (ocrelizumab) is a ...

The vendor onboarding workflow begins with a Microsoft Form, where users submit their requests. These submissions are then routed through a structured approval process involving key stakeholders, such ...

Newly approved medications for secondary progressive MS can help slow disease progression or treat specific symptoms. Most people who are diagnosed with multiple sclerosis (MS) initially have ...